TY - JOUR
T1 - Perspectives on the role of “-Omics” in predicting response to immunotherapy
AU - Di Giacomo, Anna Maria
AU - Subudhi, Sumit
AU - Vos, Wim
AU - Andreatta, Massimo
AU - Carmona, Santiago
AU - McTavish, Will
AU - Seliger, Barbara
AU - Ibrahim, Ramy
AU - Lahn, Michael
AU - Smith, Michael
AU - Eggermont, Alexander
AU - Fox, Bernard A.
AU - Maio, Michele
N1 - Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
PY - 2025/5/2
Y1 - 2025/5/2
N2 - The annual Immuno-Oncology “Think Tank” held in October 2023 in Siena reviewed the rapidly evolving systems-biological approaches which are now providing a deeper understanding of tumor and tumor microenvironment heterogeneity. Based on this understanding opportunities for novel therapies may be identified to overcome resistance to immunotherapy. There is increasing evidence that malignant disease processes are not limited to purely intracellular or genetic events but constitute a dynamic interaction between the host and disease. Tumor responses are influenced by many host tissue determinants across different cellular compartments, which can now be investigated by high-throughput molecular profiling technologies, often labelled with a suffix “-omics”. “Omics” together with ever increasing computational power, fast developments in machine learning, and high-resolution detection tools offer an unrivalled opportunity to connect high-dimensional data and create a holistic view of disease processes in cancer. This review describes advances in several state-of-the-art “-omics” approaches with perspectives on how these can be applied to the clinical development of new immunotherapeutic strategies and ultimately adopted in clinical practice.
AB - The annual Immuno-Oncology “Think Tank” held in October 2023 in Siena reviewed the rapidly evolving systems-biological approaches which are now providing a deeper understanding of tumor and tumor microenvironment heterogeneity. Based on this understanding opportunities for novel therapies may be identified to overcome resistance to immunotherapy. There is increasing evidence that malignant disease processes are not limited to purely intracellular or genetic events but constitute a dynamic interaction between the host and disease. Tumor responses are influenced by many host tissue determinants across different cellular compartments, which can now be investigated by high-throughput molecular profiling technologies, often labelled with a suffix “-omics”. “Omics” together with ever increasing computational power, fast developments in machine learning, and high-resolution detection tools offer an unrivalled opportunity to connect high-dimensional data and create a holistic view of disease processes in cancer. This review describes advances in several state-of-the-art “-omics” approaches with perspectives on how these can be applied to the clinical development of new immunotherapeutic strategies and ultimately adopted in clinical practice.
KW - Dark matter
KW - Epigenetics
KW - Immunotherapy
KW - Systems biology
KW - Tumor microenvironment
KW - “omics”-based biology
KW - Immunotherapy/methods
KW - Humans
KW - Treatment Outcome
KW - Genomics/methods
KW - Biomarkers, Tumor/genetics
KW - Tumor Microenvironment/immunology
KW - Proteomics/methods
KW - Neoplasms/immunology
KW - Metabolomics/methods
UR - https://www.scopus.com/pages/publications/105001313308
UR - https://www.mendeley.com/catalogue/41f8debd-7935-3b1e-9104-5a25598164a9/
U2 - 10.1016/j.ejca.2025.115393
DO - 10.1016/j.ejca.2025.115393
M3 - Article
C2 - 40168935
AN - SCOPUS:105001313308
SN - 0959-8049
VL - 220
JO - European Journal of Cancer
JF - European Journal of Cancer
M1 - 115393
ER -